IL279998A - Compositions and methods relating to engineered constructs with an antigen-binding site-FC - Google Patents

Compositions and methods relating to engineered constructs with an antigen-binding site-FC

Info

Publication number
IL279998A
IL279998A IL279998A IL27999821A IL279998A IL 279998 A IL279998 A IL 279998A IL 279998 A IL279998 A IL 279998A IL 27999821 A IL27999821 A IL 27999821A IL 279998 A IL279998 A IL 279998A
Authority
IL
Israel
Prior art keywords
engineered
compositions
antigen binding
binding domain
methods related
Prior art date
Application number
IL279998A
Other languages
English (en)
Hebrew (he)
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of IL279998A publication Critical patent/IL279998A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL279998A 2018-07-11 2021-01-07 Compositions and methods relating to engineered constructs with an antigen-binding site-FC IL279998A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862696618P 2018-07-11 2018-07-11
PCT/US2019/041406 WO2020014486A1 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs

Publications (1)

Publication Number Publication Date
IL279998A true IL279998A (en) 2021-03-01

Family

ID=69142016

Family Applications (1)

Application Number Title Priority Date Filing Date
IL279998A IL279998A (en) 2018-07-11 2021-01-07 Compositions and methods relating to engineered constructs with an antigen-binding site-FC

Country Status (11)

Country Link
US (1) US20220267460A1 (https=)
EP (1) EP3820519A4 (https=)
JP (1) JP2021531268A (https=)
KR (1) KR20210042326A (https=)
CN (1) CN113164591A (https=)
AU (1) AU2019302740A1 (https=)
BR (1) BR112021000392A2 (https=)
CA (1) CA3106212A1 (https=)
IL (1) IL279998A (https=)
MX (1) MX2021000287A (https=)
WO (1) WO2020014486A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10696722B2 (en) 2016-08-10 2020-06-30 Ajou University Industry-Academic Cooperation Foundation Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
SG11202104136YA (en) * 2018-10-23 2021-05-28 Dragonfly Therapeutics Inc Heterodimeric fc-fused proteins
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
KR20240114791A (ko) * 2021-11-05 2024-07-24 오슬로 유니버시테시케후스 에이치에프 IgA Fc 및 IgG Fc 이중 단백질 구조

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008137382A1 (en) * 2007-04-30 2008-11-13 Centocor, Inc. Anti-tissue factor antibodies and compositions with enhanced effector function
PL2185589T3 (pl) * 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
CA2843158A1 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
US9683044B2 (en) * 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP4299595A3 (en) * 2014-05-02 2024-03-13 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
DK3484514T3 (da) * 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
WO2018129397A1 (en) * 2017-01-06 2018-07-12 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs

Also Published As

Publication number Publication date
CA3106212A1 (en) 2020-01-16
BR112021000392A2 (pt) 2021-04-06
AU2019302740A1 (en) 2021-02-18
EP3820519A1 (en) 2021-05-19
JP2021531268A (ja) 2021-11-18
WO2020014486A1 (en) 2020-01-16
KR20210042326A (ko) 2021-04-19
CN113164591A (zh) 2021-07-23
US20220267460A1 (en) 2022-08-25
MX2021000287A (es) 2021-09-08
EP3820519A4 (en) 2022-04-20

Similar Documents

Publication Publication Date Title
EP3565595A4 (en) COMPOSITIONS AND METHODS ASSOCIATED WITH DOMAIN CONSTRUCTIONS OF BINDING TO MANIPULATED FC ANTIGEN
IL279998A (en) Compositions and methods relating to engineered constructs with an antigen-binding site-FC
IL286367A (en) Compositions and methods relating to engineered fc constructs
IL263211A (en) Compositions and methods relating to engineered fc constructs
IL280014A (en) Compositions and methods relating to engineered constructs with an antigen-binding site FC targeting CTLA-4
IL280046A (en) Compositions and methods relating to engineered constructs with an antigen-binding site FC targeted to CD38
HUE050279T2 (hu) Béta-klotho 2-es doménjéhez kötõdõ antitestek és azok alkalmazási módszerei
IL272103A (en) Antigen-binding proteins binding to 5T4 and 4-1BB, compositions and methods
SG10202107391YA (en) Compositions and methods related to engineered fc constructs
IL280044A (en) Compositions and methods relating to engineered constructs with an antigen-binding site-FC
IL257458A (en) dpep-1 binding compositions and methods of use
IL280038A (en) Compositions and methods relating to engineered constructs with an antigen-binding site FC targeting PD-L1
EP3820517A4 (en) COMPOSITIONS AND METHODS RELATED TO CCR4-TARGETED FC ANTIGEN-BINDING DOMAIN CONSTRUCTIONS
IL283757A (en) Engineered products derived from flagellin and their uses
IL279999A (en) Compositions and methods relating to engineered constructs with an antigen-binding site-FC
IL279989A (en) Compositions and methods relating to engineered constructs with an antigen-binding site-FC
HK40053036A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
HK40053031A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
HK40053032A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
HK40053033A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
IL291465A (en) Compositions and methods relating to engineered fc-antigen binding region constructs targeted to cd38
HK40017013A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
HK40053037A (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38
HK40053238A (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
HK40053035A (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1